Qualtix Stock Brief
Vertex Pharmaceuticals Incorporated (VRTX) stock analysis: business quality, valuation, and entry timing
Vertex is a biotechnology company that leads treatment of cystic fibrosis and is expanding into pain, kidney disease, and gene editing. A highly profitable core franchise funds its pipeline, which the model reads against the price of the stock. Public Qualtix model snapshot from 2026-10-26 for VRTX: business quality 77/100, above the model's stronger-company threshold and valuation Fair. Today's verdict and Entry Timing are shown after a free sign-in.
Qualtix evaluates VRTX with a rules-based model that separates business quality, valuation, entry timing, red flags, and data confidence. The model scores first; AI explanations and the full Clean Brief help explain the result afterward.
Coverage note: Qualtix can analyze supported US stocks when SEC/FMP filing data is available. The 1,000+ stock universe refers to the daily screener used for discovery, not the full analysis limit.
VRTX public evidence metrics from the latest validated Qualtix snapshot
| Metric | Value | Why it matters | Source |
|---|---|---|---|
| Revenue growth | 9.9% | 3-year revenue CAGR | FMP, computed |
| FCF margin | 30.1% | Free cash flow divided by revenue | FMP, computed |
| Operating margin | 38.6% | Profitability margin | FMP, computed |
| Gross margin | 86.0% | Revenue retained after direct costs | FMP, computed |
| Return on capital (pre-tax) | 21.9% | Operating profit before tax, divided by equity plus debt | FMP, computed |
| ROE | 21.8% | Return on equity | FMP, computed |
| Cash and debt | Cash and investments $7.9B / Debt $2.0B | Balance-sheet context | FMP, reported |
| TTM P/E | 30.0x | Price to trailing earnings | FMP, computed |
Qualtix view
- Business quality: 77/100, above the model's stronger-company threshold.
- Valuation is currently labeled Fair, which the model weighs separately from business quality.
Today's verdict
- Today's model verdict and Entry Timing for VRTX update every market day and are shown after a free sign-in.
Data and snapshot dates
- Model snapshot date: 2026-10-26.
- Financial data through: 2026-06-30.
- Scored by the current Qualtix model.
- Data-confidence status: high.
What supports the current view
- Business quality clears the model's stronger-company threshold (77/100).
- Beta of 0.32 suggests lower market sensitivity than higher-beta alternatives.
What weakens the current view
- Valuation is currently labeled Fair, so price still matters.
What changed
- Business Quality was unchanged from the previous snapshot.
What to research next
- Compare VRTX's Fair valuation label with similar companies before treating price as a clear advantage.
- Compare VRTX with AMGN and LLY to see whether the model edge is company-specific or sector-wide.
Follow Qualtix on X, TikTok, LinkedIn, YouTube.
Qualtix is for research and education only. It is not financial advice.